Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Amortizatization of Intangibles: 2020-2025

Historic Amortizatization of Intangibles for Xeris Biopharma Holdings (XERS) over the last 4 years, with Sep 2025 value amounting to $2.7 million.

  • Xeris Biopharma Holdings' Amortizatization of Intangibles changed negligibly% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $10.8 million for FY2024, which is negligibly% changed negligibly from last year.
  • According to the latest figures from Q3 2025, Xeris Biopharma Holdings' Amortizatization of Intangibles is $2.7 million, which was down 0.00% from $2.7 million recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Amortizatization of Intangibles ranged from a high of $2.7 million in Q1 2022 and a low of -$154,000 during Q1 2021.
  • Moreover, its 3-year median value for Amortizatization of Intangibles was $2.7 million (2025), whereas its average is $2.7 million.
  • Per our database at Business Quant, Xeris Biopharma Holdings' Amortizatization of Intangibles surged by 1,860.39% in 2022 and then fell by 0.04% in 2025.
  • Xeris Biopharma Holdings' Amortizatization of Intangibles (Quarterly) stood at $903,000 in 2021, then spiked by 200.22% to $2.7 million in 2022, then remained steady at $2.7 million in 2023, then remained steady at $2.7 million in 2024, then remained steady at $2.7 million in 2025.
  • Its last three reported values are $2.7 million in Q3 2025, $2.7 million for Q2 2025, and $2.7 million during Q1 2025.